Slaughter and May is advising GlaxoSmithKline – divestment of non-core assets to Aspen

Slaughter and May is advising GlaxoSmithKline plc (GSK) on a series of agreements with the Aspen Group (Aspen) as part of GSK’s strategy of simplification through focusing on core therapeutic areas. GSK will divest its anaesthesia portfolio to Aspen for £180 million plus milestones of up to £100 million. GSK and Aspen have also entered into parallel agreements to terminate their collaboration in Sub-Saharan Africa and for Aspen to exercise its option to acquire GSK’s remaining thrombosis business in certain retained markets. The agreements are subject to regulatory and anti-trust approvals.

Slaughter and May is supporting the GSK legal team which is led by Elizabeth Planell and Katie Salmon.

Richard Smith Partner
Chris McGaffin Partner
David Johnson Partner
Claire Jackson Partner
Laura Houston Partner
Jordan Ellison Partner
Kerry O'Connell Partner
Lorna Nsoatabe Partner
Simon Clark Associate
Rosemary Nelson Associate